This is a type of cancer that starts in the ducts of glands. Glands are small organs that make and release substances like milk (in the breast), digestive juices (in the pancreas), or hormones (in the prostate). Ductal carcinoma can occur in many different organs, including the breast, pancreas, prostate, and tear glands.
Every report comes from a Lived member, sent anonymously.
Have you tried Radiation Therapy for Ductal Carcinoma?
Ductal carcinoma is cancer that starts in the cells lining a duct, one of the small tubes that carry fluid through a gland. The term is used most often for breast cancer. The breast has lobules, where milk is made, and ducts, which carry milk to the nipple. Ductal carcinoma, which begins in the duct lining, is the most common type of breast cancer. In the breast it takes two main forms, and the difference shapes everything that follows. In ductal carcinoma in situ (DCIS), abnormal cells are confined inside the ducts and have not grown through the duct wall, so they cannot spread beyond the breast. DCIS is also called stage 0 or noninvasive breast cancer, and some experts describe it as a precancer because it can become invasive if left alone. In invasive ductal carcinoma, the cells have broken through the duct wall into the surrounding breast tissue, where they can reach the lymph nodes and bloodstream and spread to other parts of the body. About 3 in 4 invasive breast cancers are this type, which pathology reports may now call invasive breast carcinoma of no special type. Ductal cancers also arise in other organs. The most common pancreatic cancer, pancreatic adenocarcinoma, usually starts in the pancreas's ducts, and the prostate has a rare ductal subtype that tends to behave more aggressively than the usual form. These cancers differ from breast cancer in their causes, tests, treatment and outlook, so the rest of this page is about ductal carcinoma of the breast.
Breast ductal carcinoma develops when cells lining a duct acquire changes in their DNA that let them grow out of control. Usually the reason for those changes is unknown. In some families, an inherited change in a gene such as BRCA1 or BRCA2 raises the risk considerably; these variants also raise the risk of ovarian and some other cancers. Other factors increase risk without causing the cancer on their own: older age, a previous breast cancer or certain benign breast conditions, dense breast tissue, radiation to the chest, obesity and drinking alcohol. Longer lifetime exposure to estrogen also matters, which is why starting periods early, reaching menopause late, having a first child later in life or not at all, and taking menopausal hormone therapy are linked to higher risk. Many people with these risk factors never develop breast cancer, and many who do have no risk factor other than age. Breast cancer mostly affects women, but men can develop it too.
DCIS rarely causes symptoms. It is usually found on a screening mammogram, often as calcifications, tiny white specks on the image. Invasive ductal carcinoma may also be found on screening, or because someone notices a change, most often a new lump. In the US, the Preventive Services Task Force recommends a screening mammogram every two years for women aged 40 to 74. When a mammogram or exam finding looks suspicious, more mammogram views, ultrasound or sometimes MRI help define it, but only a biopsy can confirm cancer. A pathologist examines the tissue under a microscope to tell whether the cells are still inside the ducts (DCIS) or have invaded the surrounding tissue, and assigns a grade, which describes how abnormal and fast-growing the cells look. The tissue is also tested for features that steer treatment. Hormone receptor tests show whether the cells have receptors for estrogen or progesterone, hormones that help them grow; about 3 in 4 breast cancers have at least one. HER2 testing measures a growth-promoting protein. About 15 to 20 percent of breast cancers make too much of it (HER2-positive), which makes them grow faster but also makes them much more likely to respond to drugs that target HER2. A cancer with neither hormone receptors nor excess HER2 is called triple-negative. For invasive cancer, the nearby lymph nodes are checked, and the results together give the stage: from stage I, a small cancer that has not spread or barely reached a lymph node, to stage IV, cancer that has spread to distant organs.
DCIS is almost always treated, because there is currently no reliable way to tell which cases would go on to become invasive. Most people can choose between a lumpectomy, which removes the abnormal area with a margin of healthy tissue, and a mastectomy, which removes the whole breast; mastectomy is favored when DCIS is large or in several areas. Radiation usually follows a lumpectomy to lower the chance of DCIS or invasive cancer returning in that breast. If the DCIS is hormone receptor-positive, five years of hormone therapy, either tamoxifen or, after menopause, an aromatase inhibitor such as anastrozole, can lower the risk of a new DCIS or invasive cancer in either breast. Studies are testing whether careful monitoring alone is reasonable for some low-risk DCIS, but that is not yet standard care. Invasive ductal carcinoma is treated much like other invasive breast cancers, guided mainly by its stage, hormone receptor and HER2 status. For stages I to III, surgery is the main treatment. For early-stage cancer, lumpectomy followed by radiation gives the same survival as mastectomy, while preserving most of the breast. Some people aged 65 or older with a small, fully removed, hormone receptor-positive cancer that has not reached the lymph nodes may reasonably skip radiation if they take hormone therapy: radiation would still lower the chance of the cancer returning in the breast, but it has not been shown to help them live longer. Most people with stage I to III cancer also receive systemic therapy, medicine that travels through the whole body, to lower the chance of the cancer returning elsewhere. Hormone receptor-positive cancers are treated with hormone therapy, usually for at least five years. HER2-positive cancers are treated with HER2-targeted drugs such as trastuzumab (Herceptin), usually with chemotherapy, for up to a year. Chemotherapy is used more often for larger, faster-growing, hormone receptor-negative or HER2-positive cancers; for some hormone receptor-positive, HER2-negative cancers, a gene test on the tumor helps show whether chemotherapy would add benefit. Giving treatment before surgery can shrink a large tumor, sometimes enough to make a lumpectomy possible. When cancer has spread to distant organs (stage IV), medicines are the main treatment. Cure is very difficult at this stage, but treatment can shrink tumors or slow their growth, ease symptoms and help many people live for years. Clinical trials are an option to ask about at any stage.
The outlook depends mostly on whether the cancer is in situ or invasive, and how far it has spread when found. DCIS has an excellent outlook: more than 98 percent of people are alive five years after diagnosis, and most are cured. For US women with invasive breast cancer, five-year relative survival, which compares people with the cancer to the general population, is above 99 percent when the cancer is confined to the breast, 87 percent when it has reached nearby lymph nodes or tissues, and 32 percent when it has spread to distant organs. These figures come from people diagnosed years ago, while treatment keeps improving, and they cannot predict one person's course; grade, receptor status and how the cancer responds to treatment also matter. Treatment for early-stage disease often involves several steps, and hormone therapy continues for years after surgery and radiation end. Hormone receptor-positive cancers tend to grow more slowly but can return many years later, while hormone receptor-negative cancers that return usually do so within the first few years. Some people have breast reconstruction at the time of surgery and others later; when radiation is needed, waiting until it is finished is often better. After treatment, follow-up visits are usually every 3 to 6 months at first and about once a year after five years. People who keep breast tissue have a mammogram at least yearly. Routine blood tests and scans are not needed after most early-stage cancers; tests are done when symptoms raise a question. Hormone therapy brings its own monitoring: aromatase inhibitors can thin the bones, so bone density may be checked, and tamoxifen raises the risk of uterine cancer. Stage IV breast cancer is generally treated for life, with medicines changed when the cancer grows or side effects become too hard to tolerate.
Have any new breast lump or other breast change checked by a clinician, even after a normal mammogram, since mammograms do not find every breast cancer. Changes worth an appointment include swelling of part of a breast, dimpled or puckered skin, a nipple that turns inward, nipple discharge other than milk, red, flaky or thickened skin on the breast or nipple, and swollen lymph nodes under the arm or near the collarbone. Most breast lumps are not cancer, but only an evaluation can tell. After a diagnosis, call your care team right away rather than waiting for the next scheduled visit if a new symptom or concern about the cancer comes up between appointments. If you take tamoxifen and still have a uterus, report any unusual vaginal bleeding promptly, such as spotting after menopause, bleeding between periods or a change in your periods.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Ductal Carcinoma is like, what's helped you, or ask the community a question.